ArticleCureus2026
Tocilizumab as a Potential Alternative Therapy for Acute Exacerbation of Systemic Sclerosis-Associated Interstitial Lung Disease in a Dialysis Patient Following Immunodeficiency-Associated Lymphoproliferative Disorders.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 62-year-old woman was diagnosed with diffuse cutaneous systemic sclerosis (dcSSc), complicated by scleroderma renal crisis, resulting in maintenance dialysis. Mycophenolate mofetil (MMF) and low-dose prednisolone stabilized her interstitial lung disease (ILD). Five years after the dcSSc diagnosis, she developed brain immunodeficiency‑associated lymphoproliferative disorders. Consequently, MMF was discontinued. Three months after MMF cessation, she developed a cough and productive sputum. Imaging revealed new ground-glass opacities (GGOs) in both lungs, indicating an acute exacerbation of systemic sclerosis-associated ILD (SSc-ILD). Tocilizumab was started, resulting in the rapid resolution of symptoms and new GGOs. Although this is a single case report, the findings suggest that tocilizumab may be a viable therapeutic option for SSc-ILD exacerbation, particularly in patients with limited treatment choices due to complex comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.